Aurora B facilitates cholangiocarcinoma progression by stabilizing c-Myc

Abstract

Background: Cholangiocarcinoma (CCA), a malignancy that arises from biliary epithelial cells, has a dismal prognosis, and few targeted therapies are available. Aurora B, a key mitotic regulator, has been reported to be involved in the progression of various tumors, yet its role in CCA is still unclarified.

Methods: Human CCA tissues and murine spontaneous CCA models were used to assess Aurora B expression in CCA. A loss-of-function model was constructed in CCA cells to determine the role of Aurora B in CCA progression. Subcutaneous and liver orthotopic xenograft models were used to assess the therapeutic potential of Aurora B inhibitors in CCA.

Results: In murine spontaneous CCA models, Aurora B was significantly upregulated. Elevated Aurora B expression was also observed in 62.3% of human specimens in our validation cohort (143 CCA specimens), and high Aurora B expression was positively correlated with pathological parameters of tumors and poor survival. Knockdown of Aurora B by siRNA and heteroduplex oligonucleotide (HDO) or an Aurora B kinase inhibitor (AZD1152) significantly suppressed CCA progression via G2/M arrest induction. An interaction between Aurora B and c-Myc was found in CCA cells. Targeting Aurora B significantly reduced this interaction and accelerated the proteasomal degradation of c-Myc, suggesting that Aurora B promoted the malignant properties of CCA by stabilizing c-Myc. Furthermore, sequential application of AZD1152 or Aurora B HDO drastically improved the efficacy of gemcitabine in CCA.

Conclusions: Aurora B plays an essential role in CCA progression by modulating c-Myc stability and represents a new target for treatment and chemosensitization in CCA.

Keywords

Aurora B kinase / Cholangiocarcinoma / c-Myc / combination therapy / targeted therapy

References

[1] Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma-evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95-111.

[2] Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557-588.

[3] Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in Cholangiocarcinoma incidence in the U.S. intrahepatic disease on the rise. Oncologist. 2016;21(5):594-599.

[4] Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19-31.

[5] Lewis HL, Rahnemai-Azar AA, Dillhoff M, et al. Current management of perihilar cholangiocarcinoma and future perspectives. Chirurgia (Bucharest, Romania:1990). 2017;112(3):193-207.

[6] Park HM, Yun SP, Lee EC, et al. Outcomes for patients with recurrent intrahepatic cholangiocarcinoma after surgery. Ann Surg Oncol. 2016;23(13):4392-4400.

[7] Tsukamoto M, Yamashita YI, Imai K, et al. Predictors of cure of intrahepatic cholangiocarcinoma after hepatic resection. Anticancer Res. 2017;37(12):6971-6975.

[8] Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391-398.

[9] Hoy SM. Pemigatinib: first approval. Drugs. 2020;80(9):923-929.

[10] Storandt MH, Jin Z, Mahipal A. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. Expert Rev Anticancer Ther. 2022;22(12):1265-1274.

[11] Ohaegbulam KC, Koethe Y, Fung A, et al. The multidisciplinary management of cholangiocarcinoma. Cancer. 2023;129(2):184-214.

[12] Tang A, Gao K, Chu L, et al. Aurora kinases: novel therapy targets in cancers. Oncotarget. 2017;8(14):23937-23954.

[13] Willems E, Dedobbeleer M, Digregorio M, Lombard A, Lumapat PN, Rogister B. The functional diversity of Aurora kinases: a comprehensive review. Cell Division. 2018;13:7.

[14] Krenn V, Musacchio A. The Aurora B kinase in chromosome bi-orientation and spindle checkpoint signaling. Front Oncol. 2015;5:225.

[15] Wan B, Huang Y, Liu B, Lu L, Lv C. AURKB: a promising biomarker in clear cell renal cell carcinoma. PeerJ. 2019;7:e7718.

[16] Borah NA, Reddy MM. Aurora kinase B inhibition: a potential therapeutic strategy for cancer. Molecules. 2021;26(7):1981.

[17] Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo. Mol Cancer Ther. 2016;15(10):2314-2322.

[18] Pradhan T, Gupta O, Singh G, Monga V. Aurora kinase inhibitors as potential anticancer agents: recent advances. Eur J Med Chem. 2021;221:113495.

[19] Boss DS, Witteveen PO, van der Sar J, et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011;22(2):431-437.

[20] Schwartz GK, Carvajal RD, Midgley R, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):370-380.

[21] Lakkaniga NR, Wang Z, Xiao Y, et al. Revisiting Aurora Kinase B: a promising therapeutic target for cancer therapy. Med Res Rev. Published online November 20. 2023.

[22] Topham C, Tighe A, Ly P, et al. MYC is a major determinant of mitotic cell fate. Cancer Cell. 2015;28(1):129-140.

[23] Yang H, Liu T, Wang J, et al. Deregulated methionine adenosyltransferase α1, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans(‡). Hepatology (Baltimore, MD). 2016;64(2):439-455.

[24] Allen-Petersen BL, Sears RC. Mission possible: advances in MYC therapeutic targeting in cancer. BioDrugs. 2019;33(5):539-553.

[25] Llombart V, Mansour MR. Therapeutic targeting of “undruggable” MYC. EBioMedicine. 2022;75:103756.

[26] Duffy MJ, O’Grady S, Tang M, et al. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154.

[27] Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950-1958.

[28] Jia Y, Xie J. Promising molecular mechanisms responsible for gemcitabine resistance in cancer. Genes Dis. 2015;2(4):299-306.

[29] Shah KN, Bhatt R, Rotow J, et al. Aurora kinase a drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med. 2019;25(1):111-118.

[30] Chang X, Zhang T, Wang Q, et al. HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E. Theranostics. 2020;10(21):9721-9740.

[31] Abbasnezhad A, Salami F, Mohebbati R. A review: systematic research approach on toxicity model of liver and kidney in laboratory animals. Animal Model Exp Med. 2022;5(5):436-444.

[32] Yeh CN, Maitra A, Lee KF, et al. Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis. 2004;25(4):631-636.

[33] Yang H, Li TW, Peng J, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology. 2011;141(1):378-388.e1–4.

[34] Zhou K, Jiang Y, Feng S, et al. Establishment of image-guided radiotherapy of orthotopic hepatocellular carcinoma mouse model. Animal Model Exp Med. 2023;6(5):419-426.

[35] Zhang HE, Henderson JM, Gorrell MD. Animal models for hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis. 2019;1865(5):993-1002.

[36] Ye Y, Yang X, Li F, et al. c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model. Animal Model Exp Med. Published online October 27. 2022.

[37] Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307-321.

[38] Jiang J, Wang J, Yue M, et al. Direct phosphorylation and stabilization of MYC by Aurora B kinase promote T-cell Leukemogenesis. Cancer Cell. 2020;37(2):200-215 e5.

[39] Zheng Q, Zhang B, Li C, Zhang X. Overcome drug resistance in Cholangiocarcinoma: new insight into mechanisms and refining the preclinical experiment models. Front Oncol. 2022;12:850732.

[40] Azzariti A, Bocci G, Porcelli L, et al. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. Br J Cancer. 2011;104(5):769-780.

[41] Fatma H, Maurya SK, Siddique HR. Epigenetic modifications of c-MYC: role in cancer cell reprogramming, progression and chemoresistance. Semin Cancer Biol. 2022;83:166-176.

[42] Yao J, Huang M, Shen Q, et al. c-Myc-PD-L1 Axis sustained gemcitabine-resistance in pancreatic cancer. Front Pharmacol. 2022;13:851512.

[43] Zhang Y, Chen HX, Zhou SY, et al. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Mol Cancer. 2015;14:56.

[44] Bavetsias V, Linardopoulos S. Aurora kinase inhibitors: current status and outlook. Front Oncol. 2015;5:278.

[45] Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012;30(6):2411-2432.

[46] Gully CP, Zhang F, Chen J, et al. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer. 2010;9:42.

[47] Aihara A, Tanaka S, Yasen M, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. 2010;52(1):63-71.

[48] Mori N, Ishikawa C, Senba M, Kimura M, Okano Y. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt’s and Hodgkin’s lymphomas. Biochem Pharmacol. 2011;81(9):1106-1115.

[49] Ghanizadeh-Vesali S, Zekri A, Zaker F, et al. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia. Ann Hematol. 2016;95(7):1031-1042.

[50] Sun XX, Li Y, Sears RC, Dai MS. Targeting the MYC ubiquitination-proteasome degradation pathway for cancer therapy. Front Oncol. 2021;11:679445.

[51] Farrell AS, Sears RC. MYC degradation. Cold Spring Harb Perspect Med. 2014;4(3):a014365.

[52] Gully CP, Velazquez-Torres G, Shin JH, et al. Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A. 2012;109(24):E1513-E1522.

[53] Olivero CE, Martínez-Terroba E, Zimmer J, et al. p53 activates the long noncoding RNA Pvt1b to inhibit Myc and suppress tumorigenesis. Mol Cell. 2020;77(4):761-774 e8.

[54] Larsen SL, Yde CW, Laenkholm AV, et al. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. BMC Cancer. 2015;15:239.

[55] Tanaka K, Yu HA, Yang S, et al. Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM-and PUMA-mediated apoptosis. Cancer Cell. 2021;39(9):1245-1261 e6.

[56] Shah PA, Sambandam V, Fernandez AM, et al. Sustained Aurora kinase B expression confers resistance to PI3K inhibition in head and neck squamous cell carcinoma. Cancer Res. 2022;82(23):4444-4456.

[57] Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine.Ann Oncol. 2006;17(suppl 5):v7-v12.

[58] Egli M, Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Res. 2023;51(6):2529-2573.

[59] Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16(6):630-643.

[60] Nishina K, Piao W, Yoshida-Tanaka K, et al. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun. 2015;6:7969.

RIGHTS & PERMISSIONS

2023 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.